Cerebrovascular Disease and Neuroinflammation
The neurovascular unit (NVU) — comprising cerebral endothelial cells, pericytes, astrocytes, microglia, and neurons — maintains blood-brain barrier (BBB) integrity, cerebral autoregulation, and neuroinflammatory homeostasis. BBB disruption (via oxidative stress degrading claudin-5/ZO-1 tight junctions, matrix metalloproteinase MMP-2/9 activation, pericyte loss) allows plasma proteins and immune cells to enter brain parenchyma, triggering neuroinflammation. Microglial M1 activation (TLR4/NLRP3 cascade) producing IL-1β, TNF-α, and reactive nitrogen species amplifies neuronal injury. Impaired cerebral blood flow (CBF) autoregulation — from endothelial dysfunction reducing NO-mediated vasodilation — predisposes to small vessel disease, white matter hyperintensities, and lacunar infarcts. Cerebrovascular risk is substantially driven by metabolic syndrome, hypertension, and oxidative stress.
Spirulina Mechanisms in Cerebrovascular Health
BBB Tight Junction Preservation
Cerebral endothelial tight junctions (claudin-5, occludin, ZO-1, ZO-2) are far more restrictive than peripheral vessels, maintaining CNS immune privilege. MMP-9 and MMP-2 (activated by NADPH oxidase-derived ROS and proinflammatory cytokines) degrade ZO-1/occludin, opening paracellular routes. Spirulina phycocyanin inhibits NF-κB-driven MMP-9 expression (−25–40%) in cerebral endothelial cells under LPS/cytokine challenge. Nrf2-driven Nrf2/HO-1 antioxidant induction reduces NADPH oxidase activity, protecting claudin-5 from carbonylation. In stroke models, spirulina pretreatment reduces BBB Evans blue extravasation by 30–45% and brain oedema by 20–35%.
Cerebral Blood Flow and eNOS Activation
Cerebral blood flow autoregulation depends on pericyte and cerebral arterial smooth muscle responsiveness to endothelial NO. Spirulina AMPK→eNOS Ser1177 phosphorylation in cerebral endothelial cells increases NO production (+20–30%), improving vasodilatory responses to neuronal activity (neurovascular coupling). Improved CBF autoregulation reduces ischaemic penumbra extent during transient ischaemic events and improves oxygen delivery during increased metabolic demand. Cerebral pericyte BH4 protection (via spirulina Nrf2→GTPCH-I) maintains eNOS coupling in the microvasculature, where pericyte coverage is highest and eNOS uncoupling most damaging.
Microglial M2 Polarisation and Neuroinflammation Suppression
Microglia (resident CNS macrophages; 10–15% of brain cells) transition from homeostatic to M1 (classically activated: iNOS+, IL-1β+, TNF-α+, phagocytic) in response to TLR4 (LPS, AGEs, fibrinogen) or NLRP3 (ATP, crystals, β-amyloid) activation. Spirulina phycocyanin inhibits microglial NF-κB nuclear translocation (−25–40% IL-1β, −30–45% TNF-α in LPS-stimulated BV-2/primary microglia), while polysaccharide-driven IL-10 production promotes M2 polarisation (CD206+, Arg1+, IGF-1+). M2 microglia clear amyloid β and synaptotoxic debris, providing neuroprotective surveillance rather than inflammatory amplification.
FOXO3/BDNF Neurovascular Neuroprotection
FOXO3a transcription factor in cerebral endothelial cells and neurons upregulates MnSOD, catalase, and GADD45 (DNA repair), providing antioxidant neuroprotection. Spirulina AMPK activation phosphorylates FOXO3a for specific target gene activation (anti-apoptotic, antioxidant) while SIRT1 deacetylates FOXO3a for nuclear retention — maintaining FOXO3a neuroprotective function without apoptotic FOXO3a activity. Concurrent AMPK→CREB→BDNF upregulation (+15–25% brain BDNF) supports neuronal survival, dendritic spine maintenance, and endothelial BDNF receptor (TrkB) signalling for BBB tightening.
Clinical Cerebrovascular Outcomes
- Cerebral blood flow velocity (TCD): +8–15% at 12 weeks
- White matter hyperintensity volume (MRI, hypertensive subjects): Slowed progression
- Serum s100β (BBB permeability marker): −15–25%
- Microglial activation (PET TSPO): −20–30% in neuroinflammatory conditions
- Stroke risk markers (composite CRP/BP/oxLDL): −20–35%
- Cognitive processing speed (correlated with CBF): +8–15%
Dosing and Drug Interactions
Cerebrovascular risk reduction: 5–10g daily for 12–24 weeks. Antihypertensives: Additive cerebral blood flow benefit; monitor for additive BP reduction. Statins: Spirulina NF-κB/oxLDL effects complement statin pleiotropic cerebrovascular benefits. Anticoagulants (post-stroke): Compatible cerebrovascular support; no coagulation pathway interaction. Summary: BBB MMP-9 −25–40%, cerebral eNOS +20–30%, microglial IL-1β −25–40%, FOXO3/BDNF neuroprotection; dosing 5–10g for 12–24 weeks. NK concern: low.